Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budigalimab + pemetrexed + carboplatin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This drug is a combination therapy of three agents—**budigalimab** (a humanized IgG1 monoclonal antibody targeting programmed cell death protein 1 [PD-1]), **pemetrexed** (a multi-targeted antifolate chemotherapy), and **carboplatin** (a platinum-based DNA crosslinking chemotherapy). Budigalimab blocks PD-1 signaling, thereby enhancing T-cell mediated immune responses against cancer cells. Pemetrexed inhibits multiple folate-dependent enzymes essential for DNA synthesis and cell replication. Carboplatin forms DNA crosslinks, impairing DNA replication and transcription, leading to apoptosis. The combination is currently being investigated for first-line treatment of **metastatic non-squamous non-small cell lung cancer (NSCLC)**, especially in clinical trials assessing immuno-chemotherapy regimens[1][2][3][5].
- Other names
- budigalimab + pemetrexed + carboplatin
02
Targets
GART (GAR transformylase)DNAPDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on budigalimab + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budigalimab + pemetrexed + carboplatin.